Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
Cutaneous adverse effects of imatinib mesylate (Glivec) are common and various types of skin eruptions have been reported. We report here a 57-year-old man who presented with lichen planus-like lesions on his extremities and palmoplantar hyperkeratosis due to the use of imatinib mesylate for chronic myeloid leukaemia. The skin lesions improved after discontinuation of imatinib mesylate but re-administration of the drug at a lower dose provoked a mild recurrence. He could, however, continue to take the drug at the lower dose and his skin lesions were well-controlled by topical corticosteroid treatment. The literature on lichenoid drug eruption due to imatinib mesylate is reviewed.
Kuraishi
Natsuki
N
Department of Dermatology, Gunma University Graduate School of Medicine, 3-39-22, Showamachi, Maebashishi, Gunma 371-8511, Japan. natsukik@showa.gunma-u.ac.jp
Nagai
Yayoi
Y
Hasegawa
Michiko
M
Ishikawa
Osamu
O
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D003879:Dermatologic Agents / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007645:Keratoderma, Palmoplantar / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D017512:Lichenoid Eruptions / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012008:Recurrence; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D001549:Benzamides; D003879:Dermatologic Agents; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate